Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577860 | 0.96 | GAA (0.53) | LMNASMN1; SMN2F10GAAALDH1A1 | |
| SCHEMBL14586598 | 0.86 | LMNA (0.55) | LMNASMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL5577335 | 0.86 | KCNH2 (0.53) | ACKR3CXCR3 | |
| Hydrochloric Acid SCHEMBL5577422 | 0.85 | LMNA (0.54) | LMNASMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL5577735 | 0.85 | LMNA (0.46) | LMNAMAPTACKR3ACHESIGMAR1 | |
| SCHEMBL5577317 | 0.84 | GAA (0.51) | LMNASMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL5577845 | 0.83 | ACKR3 (0.53) | LMNASMN1; SMN2F10GAAALDH1A1 | |
| SCHEMBL5577315 | 0.83 | GAA (0.57) | LMNASMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL5577627 | 0.82 | GAA (0.48) | LMNASMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL5577897 | 0.82 | GAA (0.54) | LMNASMN1; SMN2GAAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | LMNA 4819/4885SMN1; SMN2 2012/4885F10 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.